Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels-Reference-Cited by-同舟云学术

Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels

Published:2015-05 Issue:3 Volume:11 Page:252-258
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Shanafelt Tait D.¹,Borah Bijan J.¹,Finnes Heidi D.¹,Chaffee Kari G.¹,Ding Wei¹,Leis Jose F.¹,Chanan-Khan Asher A.¹,Parikh Sameer A.¹,Slager Susan L.¹,Kay Neil E.¹,Call Tim G.¹

Affiliation:

1. Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; and Mayo Clinic, Jacksonville, FL

Abstract

Although ibrutinib and idelalisib are profound treatment advances, they will dramatically increase individual out-of-pocket and societal costs of caring for patients with CLL.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.2014.002469

Reference53 articles.

1. Cancer statistics, 2012

2. Predicting clinical outcome in CLL: how and why

3. Chlorambucil in Indolent Chronic Lymphocytic Leukemia

4. Incidence of Chronic Lymphocytic Leukemia in Olmsted County, Minnesota, 1935 Through 1989, With Emphasis on Changes in Initial Stage at Diagnosis

5. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysis;Scientific Reports;2024-07-27

2. Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment;Leukemia & Lymphoma;2024-07-09

3. Comparison of Financial Hardship and Healthcare Utilizations Associated with Cancer in the United States Medicare Programs during the COVID-19 Pandemic;Healthcare;2024-05-20

4. Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US;The Oncologist;2024-01-27

5. Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study;BMC Health Services Research;2023-12-05